BridgeBio Pharma's Soaring Stock – Will the Upward Momentum Last?

BridgeBio Pharma stock is trading -14.73% below its average target price of $47.17 after marking a 4.6% during today's evening session. Analysts are giving the small-cap Pharmaceutical company an average rating of buy and target prices ranging from $28.0 to $60.0 per share.

The stock has an unusually large proportion of its shares sold short at 15.0%, and a short ratio of 12.74. Since 5.76% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 94.8% of BridgeBio Pharma's shares being owned by this investor type.

Institutions Invested in BridgeBio Pharma

Date Reported Holder Percentage Shares Value
2023-09-30 Kohlberg Kravis Roberts & Co. L.P. 18% 31,060,971 $1,249,272,291
2023-09-30 Viking Global Investors, L.P. 14% 25,120,991 $1,010,366,288
2023-09-30 Vanguard Group Inc 6% 11,275,981 $453,519,969
2023-09-30 Blackrock Inc. 5% 9,249,943 $372,032,718
2023-09-30 Aisling Capital Management LP 3% 6,068,125 $244,059,994
2023-09-30 Laurion Capital Management, LP 3% 5,651,039 $227,284,795
2023-09-30 State Street Corporation 3% 5,040,414 $202,725,457
2023-09-30 Cormorant Asset Management, LP 3% 4,662,530 $187,526,962
2023-09-30 HHLR Advisors, LTD 2% 2,782,750 $111,922,208
2023-09-30 Pictet Asset Management Holding SA 2% 2,740,022 $110,203,688

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on BridgeBio Pharma.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.